Elemento Lab

Publications

Found 527 results
Journal Article
Kudman S, Semaan A, Assaad MAl, Gogineni S, M Martin L, Mathew S, Elemento O, Wilkes DC, Mosquera JMiguel.  2024.  Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine.. Curr Protoc. 4(6):e1093.
Sivakumar R, Chan M, Shin JStella, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS.  2019.  Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.. Oncoimmunology. 8(12):e1670019.
Hanif SZ, Au CMCherie, Torregroza I, Kutz C, Jannath SY, Fabiha T, Bhinder B, Washburn MP, Devost D, Liu S et al..  2025.  The Orphan G Protein-Coupled Receptor GPR52 is a Novel Regulator of Breast Cancer Multicellular Organization.. bioRxiv.
Cheng APellan, Rusinek I, Sossin A, Widman AJ, Meiri E, Krieger G, Hirschberg O, Tov DShem, Gilad S, Jaimovich A et al..  2025.  Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules.. bioRxiv.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Elemento O, Bulusu KC.  2024.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. bioRxiv.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Bulusu KC, Elemento O.  2026.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. Res Sq.
Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al..  2012.  A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.. Clin Cancer Res. 18(7):2032-8.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Kuo H-H, Bhinder B, Gokozan HN, Gorski K, Chandra P, Manohar J, Guevara D, Otilano J, Moyer J, Tranquille M et al..  2026.  Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.. Sci Adv. 12(26):eadz3351.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. 6(4):102029.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
K Devi SP, Wang E, Jaiswal A, Konieczny P, Kim T-G, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN et al..  2025.  PD-1 is requisite for skin T cell formation and specification by TGFβ.. Nat Immunol. 26(8):1339-1351.
Park K, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T, Borczuk A, Mosquera JMiguel, Pan Q, Sboner A et al..  2020.  Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med.
Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE.  2022.  Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.. medRxiv.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z et al..  2018.  Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.. Mol Cell. 70(3):531-544.e9.
De Boni L, Claridge S, Nath S, Tofani K, Stein BD, Park E, Steiner S, Elemento O, Pauli C, Hopkins BD.  2026.  Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors.. iScience. 29(3):114954.
Kandola MS, Kulm S, Kim LK, Markowitz SM, Liu CF, Thomas G, Ip JE, Lerman BB, Elemento O, Cheung JW.  2023.  Population-Level Prevalence of Rare Variants Associated With Atrial Fibrillation and its Impact on Patient Outcomes.. JACC Clin Electrophysiol. 9(7 Pt 2):1137-1146.
Glass J, Elemento O.  2024.  The power and perils of large language models in haematology.. Br J Haematol. 205(6):2190-2192.
Carty MA, Elemento O.  2016.  Practical Analysis of Genome Contact Interaction Experiments.. Methods Mol Biol. 1418:177-89.
Hajirasouliha I, Elemento O.  2020.  Precision medicine and artificial intelligence: overview and relevance to reproductive medicine.. Fertil Steril. 114(5):908-913.
Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI et al..  2019.  Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.. Clin Cancer Res. 25(17):5271-5283.